Arkansas is currently home to 660 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Little Rock, Jonesboro, Hot Springs and Fayetteville. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
NCT04510597
Recruiting
This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, pembrolizumab, and avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow an... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2024
Locations: Mercy Hospital Fort Smith, Fort Smith, Arkansas
Conditions: Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Register for Updates
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
NCT04205968
Recruiting
This phase II trial studies how well ramucirumab and paclitaxel or the FOLFIRI regimen (leucovorin calcium, fluorouracil, and irinotecan hydrochloride) work in treating patients with small bowel cancers that have spread extensively to other anatomic sites (advanced) or are no longer responding to treatment (refractory). Ramucirumab is a monoclonal antibody that attaches to and inhibits a molecule called VEGFR-2. This may restrain new blood vessel formation therefore reducing nutrient supply to t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2024
Locations: Mercy Hospital Fort Smith, Fort Smith, Arkansas
Conditions: Metastatic Small Intestinal Adenocarcinoma, Stage III Small Intestinal Adenocarcinoma AJCC v8, Stage IIIA Small Intestinal Adenocarcinoma AJCC v8, Stage IIIB Small Intestinal Adenocarcinoma AJCC v8, Stage IV Small Intestinal Adenocarcinoma AJCC v8
Register for Updates
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
NCT03678025
Recruiting
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/14/2024
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Register for Updates
Child and Adolescent Registry for Participants With Narcolepsy
NCT04899947
Recruiting
CATNAP is a patient registry designed to improve the understanding of the natural history of narcolepsy in pediatric patients. Descriptive statistics on disease characteristics will be performed. The study has 16 active clinical sites and a virtual site that widens participation to anywhere in the United States. For more information about the study or to access the Online Patient Enrollment System, visit the CATNAP website: https://catnap.healthie.net/welcome or email catnap@pulseinfoframe.com.... Read More
Gender:
ALL
Ages:
17 years and below
Trial Updated:
08/13/2024
Locations: University of Arkansas, Fayetteville, Arkansas
Conditions: Narcolepsy
Register for Updates
Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Chemotherapy
NCT04829539
Recruiting
This phase III trial compares BBT-CI to HEAL for the reduction of insomnia in patients with stage I-IV cancer who are receiving cancer treatment. Cancer treatment can cause side effects such as sleep problems. Sleep problems such as insomnia, are common for cancer patients. Insomnia can be described as difficulty falling asleep, waking up many times during the night or waking up earlier than patient would like. Insomnia can increase fatigue and worsen quality of life. This trial may help researc... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2024
Locations: Mercy Hospital Fort Smith, Fort Smith, Arkansas
Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Register for Updates
Results of Patients With Glaucoma Undergoing Minimally Invasive Glaucoma Surgery in Conjunction With Cataract Surgery
NCT05624398
Recruiting
This study is designed to determine how well patients with glaucoma can see following cataract surgery with a special type of lens called an extended-depth-of-focus (EDOF) lens. This lens is intended to reduced the patients need for glasses following cataract surgery. Patients will also undergo a minimally invasive type of glaucoma surgery using a special type of stent to reduce eye pressure, with the goal of better glaucoma control and the reduction in the need for medications to control eye pr... Read More
Gender:
ALL
Ages:
45 years and above
Trial Updated:
08/11/2024
Locations: Vold Vision P.L.L.C., Fayetteville, Arkansas
Conditions: Glaucoma, Open-Angle, Cataract
Register for Updates
A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects
NCT03893045
Recruiting
This is a Phase 3, randomized, open-label, multicenter, study in male and female pediatric subjects (2 years to \<18 years of age) with IDA, or felt by their clinician to be at risk of developing IDA. This study allows for enrollment of subjects with IDA regardless of etiology, except for CKD subjects (pediatric CKD subjects are being studied in a separate ferumoxytol protocol).
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
08/09/2024
Locations: Arkansas Children's Hospital, Little Rock, Arkansas
Conditions: Iron Deficiency Anemia
Register for Updates
Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)
NCT06295367
Recruiting
This clinical trial evaluates the effect of Cost Communication and Financial Navigation (CostCOM) intervention on adherence to care and financial burden in cancer patients. Many cancer patients experience financial hardship due to high medical out of pocket costs (OOPC), changes in employment, income and insurance. Financial hardship can lead to a delay or a stop in cancer care, and is linked to poor quality of life. Financial navigation programs, such as CostCOM, provide financial counseling, e... Read More
Gender:
ALL
Ages:
All
Trial Updated:
08/08/2024
Locations: Mercy Hospital Fort Smith, Fort Smith, Arkansas
Conditions: Malignant Solid Neoplasm
Register for Updates
Mobile Health for Adherence in Breast Cancer Patients
NCT06112613
Recruiting
This clinical trial compares the use of the connected customized treatment platform (CONCURxP), consisting of using a medication monitoring device called WiseBag along with text message reminders for missed or extra medication events, to enhanced usual care (EUC), where patients only use the WiseBag, to monitor medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor. To ensure CDK4/6 inhibitors achieve their full clinical benefit, patients need to take th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2024
Locations: Mercy Hospital Fort Smith, Fort Smith, Arkansas
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Breast Carcinoma, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
Register for Updates
To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring
NCT04597359
Recruiting
This phase II trial studies how well green tea catechins work in preventing progression of prostate cancer from a low risk stage to higher risk stages in men who are on active surveillance. Green tea catechins may stabilize prostate cancer and lower the chance of prostate growing.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
08/08/2024
Locations: Highlands Oncology Group - Fayetteville, Fayetteville, Arkansas
Conditions: Prostate Carcinoma
Register for Updates
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
NCT04566328
Recruiting
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spread... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2024
Locations: Mercy Hospital Fort Smith, Fort Smith, Arkansas
Conditions: Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma
Register for Updates
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
NCT04462406
Recruiting
This phase II trial investigates how well biomarkers on PET/CT imaging drive early discontinuation of anti-PD-1 therapy in patients with stage IIIB-IV melanoma that cannot be removed by surgery (unresectable). Anti-PD-1 therapy has become a standard therapy option for patients with unresectable melanoma. This trial is being done to determine if doctors can safely shorten the use of standard of care anti-PD1 therapy for melanoma by using biomarkers seen on PET/CT imaging and tumor biopsy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2024
Locations: Mercy Hospital Fort Smith, Fort Smith, Arkansas
Conditions: Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Acral Lentiginous Melanoma, Unresectable Melanoma, Unresectable Mucosal Melanoma
Register for Updates